Accustem Sciences Inc · OTC:ACUT
Accustem Sciences — Investor Presentation (September 2026)
15 slides from Accustem Sciences's investor presentation, Sep 30, 2026
Slide 1: Investor Presentation
eo = =, ee ACCUSTec Building Better Oncology Tools Investor Presentation AR ACCUSTEM
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. The
Slide 3: Company Overview
COMPANY OVERVIEW Our mission at AccuStem (OTCQB: ACUT) is to provide proprietary diagnostic tools that address unanswered clinical questions to improve outcomes for patients and return shareholder value Our primary product candidate, MSC, evaluates 24 miRNAs to stratify lung nodules according to the
Slide 4: AccuStem at a Glance
ACCUSTEM AT A GLANCE LUNG CANCER PROGRAM STEMNESS PROGRAM (BREAST CANCER) EFFICIENT CORPORATE EXECUTION • In-licensed MSC assay from Istituto • In-licensed StemPrintER assay from • Proven leadership team with nearly Nazionale dei Tumori (INT) Istituto Europeo di Oncologia (IEO) 60 combined years of
Slide 5: AccuStem Product Pipeline
ACCUSTEM PRODUCT PIPELINE AccuStem’s mission is to provide proprietary diagnostic tools that address unanswered clinical questions to improve outcomes for patients and return shareholder value Our capital efficient business model, low debt burden and broad IP protection will maximize investor return
Slide 6: AccuStem Lung Program
ACCUSTEM LUNG PROGRAM LUNG NODULES LUNG CANCER • More than 15M patients eligible for LDCT • >236K new cancers diagnosed annually screening (<5% screened today) in the US • ~1.6M nodules identified annually in the • Five-year survival is ~22% US (>90% are benign) • ACUT will support treatment plannin
Slide 7: Validation of MSC in Lung Cancer Screening (MILD Trial)
VALIDATION OF MSC IN LUNG CANCER SCREENING (MILD TRIAL) • Prospective MILD Trial1 • Investigators wanted to determine whether MSC could improve accuracy of LDCT screening • Study enrolled 939 patients • MSC+LDCT demonstrated 99% NPV for ruling out cancer • Combing MSC with LDCT led to a five-fold re
Slide 8: Validation of MSC in Lung Cancer Screening (BioMILD Trial)
VALIDATION OF MSC IN LUNG CANCER SCREENING (BIOMILD TRIAL) MSC Stratification of Lung Nodules1 MSC Identification of Lung Cancer in CT+ Patients2 MSC significantly improves the accuracy of LDCT screening for MSC+ patients are more than 4 times as likely to have patients at risk of developing lung ca
Slide 9: MSC Integration into Lung Cancer Diagnostic Workup Process
MSC INTEGRATION INTO LUNG CANCER DIAGNOSTIC WORKUP PROCESS Nodule Detected Clinical Risk Assessment Patient Triage Assessed Risk of Lung Cancer High Risk ~10% of patients MSC Test High Risk: Low Risk: >5% Clinical Indeterminate Risk Score 1 Risk Biopsy/Surgery LDCT Surveillance ~80% of patients Very
Slide 10: AccuStem Breast Cancer and Stemness Program
ACCUSTEM BREAST CANCER AND STEMNESS PROGRAM 2M+ new breast cancer diagnoses annually • No genomic tests to inform surgical approach, benefit of radiation StemPrintER is a novel 20-gene test designed to measure the "stemness" of tumors • By evaluating the underlying "stem" biology of tumors, we belie
Slide 11: Validation of StemPrintER in Breast Cancer
VALIDATION OF STEMPRINTER IN BREAST CANCER 1 2 N= 574 N= 644 N= 344 N= 432 StemPrintER is highly prognostic for outcomes StemPrintER outperformed the market leader- in early-stage breast cancer OncotypeDx- in the TransATAC cohort 1. Pece, et al. Ebiomedicine. 2019; 2. Pece, et al. Eur J Cancer. 2022
Slide 12: Our Approach to Breast Cancer
OUR APPROACH TO BREAST CANCER Guideline- ER StemPrintER* EndoPredict Breast Cancer Index supported testing: PR MammaPrint MammaPrint HER2 OncotypeDx Prosigna “For treatment planning prior to chemotherapy selection, we do not currently possess tools to determine the most appropriate interventions, sp
Slide 13: Our Leadership Team and Approach: A Proven Track Record
OUR LEADERSHIP TEAM AND APPROACH: A PROVEN TRACK RECORD WENDY BLOSSER, CEO JEFF FENSTERER, COO JOE FLANAGAN, CBO KEEREN SHAH, CFO ü 25 years of success ü 20-year track record in ü 18 years of strategic ü 20 years of experience building organizations diagnostic leadership in expertise with in control
Slide 14: Investment and Company Highlights
INVESTMENT AND COMPANY HIGHLIGHTS ü Management team with wide-ranging leadership experience across various functional areas, deep relationships with luminary US institutions and a track record of successful launch/relaunch strategies ü MSC’s level 1 data, published in several top tier journals, posi
Slide 15: Thank You for Your Consideration
THANK YOU FOR YOUR CONSIDERATION [email protected] | Accustem.com Private and Confidential. Not for Distribution
AccuStem Sciences — Investor Presentation (September 2026) on 6ix